Press releases
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
- Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
- Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:STU) traded at 65.50, -19.14% below its 52-week high of 81.00, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 65.50 |
---|---|
High | 66.00 |
Low | 65.50 |
Bid | 66.00 |
Offer | 66.50 |
Previous close | 66.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.71m |
Free float | 16.66m |
P/E (TTM) | 24.43 |
Market cap | 1.26bn USD |
EPS (TTM) | 2.91 USD |
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼